US7599161095 - Common Stock
REPLIGEN CORP
NASDAQ:RGEN (4/26/2024, 2:21:51 PM)
166.86
+1.2 (+0.72%)
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,025 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
REPLIGEN CORP
Building 1, Suite 100, 41 Seyon Street
Waltham MASSACHUSETTS 02453
P: 17814499560
CEO: Tony J. Hunt
Employees: 2025
Website: https://www.repligen.com/
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life...
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of...
Here you can normally see the latest stock twits on RGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: